Unweighted average TNFi survival rates in patients with rheumatoid arthritis.
| TNFi | 1st Treatment Line, % Survival | 2nd Treatment Line, % Survival | ||
|---|---|---|---|---|
| 12 Months Followup | 12–24 Months Followup | 12 Months Followup | 12–24 Months Followup | |
| Adalimumab | 70 (n = 17,783) | 59 (n = 11,616) | 55 (n = 1341) | 43 (n = 1061) |
| Certolizumab pegol | 62 (n = 26) | 72 (n = 628) | Not reported | 38 (n = 253) |
| Etanercept | 71 (n = 25,344) | 63 (n = 15,587) | 61 (n = 1005) | 53 (n = 810) |
| Golimumab | 63 (n = 85) | 68 (n = 339) | 66 (n = 51) | 57 (n = 282) |
| Infliximab | 69 (n = 15,685) | 57 (n = 12,796) | 69 (n = 723) | 39 (n = 349) |
TNFi: tumor necrosis factor inhibitor.